Background: The aim of this study was to determine the prevalence and severity of dry eye syndrome in a group of Mexican residents of different surgical specialties.
Methods: A cross-sectional descriptive study where the residents were studied using the Ocular Surface Disease Index, together with diagnostic tests for dry eye syndrome, such as tear breakup time, Oxford Schema, Schirmer's test I, and meibomian gland dysfunction testing. Statistical analyses were performed by Pearson's chi-squared test for categorical variables and student's t-test for quantitative variables. Any P value < 0.05 was considered statistically significant.
Results: One hundred and twenty-three residents were included (246 eyes); 90 (73 %) were male and 33 (27 %) were female. The mean age was 27.8 ± 2.1 years. A higher number of residents with dry eye syndrome was found in the cardiothoracic surgery (75 %) and otorhinolaryngology (71 %) specialties; 70 % of them reported ocular symptoms, with teardrop quality involvement in >50 % of them.
Conclusions: We found a prevalence of 56 % for mild-to-moderate/severe stages of the condition. Their presence in the operating room predisposes surgical residents to dry eye syndrome because of environmental conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947365 | PMC |
http://dx.doi.org/10.1186/s12886-016-0292-3 | DOI Listing |
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China.
Background: Adverse events (AE) in dupilumab induced ocular surface diseases (DIOSD) have raised concerns regarding its safety. The objective of this study was to evaluate DIOSD by employing database analysis and clinical case review, along with mechanism analysis.
Research Design And Methods: Database AE data were extracted from FAERS from 2017 Quarter 1 (Q1) to 2023 Q1.
Ocul Surf
December 2024
Centre for Ocular Research and Education (CORE), School of Optometry and Vision Science, University of Waterloo, Canada; Optometry and Vision Science Research Group, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; Department of Ophthalmology, Aotearoa New Zealand National Eye Centre, The University of Auckland, New Zealand.
Aims: To understand current clinical management of dry eye disease (DED), based on its perceived severity and subtype by practitioners across the world.
Methods: The content of the anonymous survey was chosen to reflect the DED management strategies reported by the Tear Film and Ocular Surface Society (TFOS) 2 Dry Eye Workshop (DEWS II). Questions were designed to ascertain practitioner treatment choice, depending on the subtype and severity of DED.
Sci Rep
December 2024
Eye Center, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuhan, 430060, Hubei, China.
Dry Eye Disease (DED) is a common condition worldwide, with smoking being recognized as a possible aggravating factor. Although observational studies have indicated a potential correlation, the findings have been inconclusive. In the study, Mendelian randomization (MR) analysis is used to investigate this potential causal relationship.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Ophthalmology, Zhangye People's Hospital Affiliated to Hexi University, Zhangye, China.
Objective: Blood component therapy has shown promising potential as an emerging treatment for dry eye disease; however, it remains unclear which specific blood component is the most effective. This study aims to compare the efficacy of different blood components in the treatment of dry eye disease through a network meta-analysis, with the goal of providing the latest and most reliable evidence for clinical practice.
Methods: We conducted a systematic search of the PubMed, Web of Science, Cochrane, Embase, and Scopus databases, with the search concluding on June 1, 2024.
Ocul Surf
December 2024
AZURA Ophthalmics, Tel-Aviv, Israel.
Background: Contact lens discomfort (CLD) is a common problem for CL wearers, and patients with CLD often have changes in meibomian gland function and structure. In a Phase 2 trial AZR-MD-001 0.5% (AZR) ophthalmic ointment improved meibomian gland dysfunction (MGD) in non-lens wearers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!